Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | F3 | P13726 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | DRD5 | P21918 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21255278 | 1.00 | HTR1A (0.58) | HTR1AADRA1AHSD11B1ACHEF3 | |
| SCHEMBL51099 | 1.00 | HTR1A (0.58) | HTR1AADRA1AHSD11B1ACHEF3 | |
| SCHEMBL51178 | 1.00 | HTR1A (0.58) | HTR1AADRA1AHSD11B1ACHEF3 | |
| SCHEMBL51308 | 1.00 | HTR1A (0.58) | HTR1AADRA1AHSD11B1ACHEF3 | |
| Hydrochloric Acid SCHEMBL50938 | 0.99 | HTR1A (0.56) | HTR1AADRA1AHSD11B1ACHEF3 | |
| Hydrochloric Acid SCHEMBL50121 | 0.99 | HTR1A (0.56) | HTR1AADRA1AHSD11B1ACHEF3 | |
| Hydrochloric Acid SCHEMBL253095 | 0.99 | HTR1A (0.56) | HTR1AADRA1AHSD11B1ACHEF3 | |
| SCHEMBL8067114 | 0.86 | HTR1A (0.51) | HTR1AADRA1AHSD11B1CYP3A4DRD2 | |
| SCHEMBL8057856 | 0.86 | HTR1A (0.51) | HTR1AADRA1AHSD11B1CYP3A4DRD2 | |
| SCHEMBL10760426 | 0.82 | HTR1A (0.84) | HTR1AHSD11B1DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3653210-A1 | TREATMENT OF DYSKINESIA RELATED DISORDERS | H. Lundbeck A/S (DK) | 2020-05-20 | — | — | EP | disclosed |
| EP-3009437-A1 | A CATECHOLAMINE DERIVATIVE USEFUL FOR THE TREATMENT OF PARKINSON'S DISEASE | H. Lundbeck A/S (DK) | 2016-04-20 | — | — | EP | disclosed |
| EP-2197883-B1 | Catecholamine derivative useful for the treatment of parkinson's disease | LUNDBECK & CO AS H (DK) | 2015-11-18 | — | — | EP | disclosed |
| EP-2662358-A1 | Catecholamine derivatives and prodrugs thereof | H. Lundbeck A/S (DK) | 2013-11-13 | — | — | EP | disclosed |
| US-20120108624-A1 | TREATMENT OF DYSKINESIA RELATED DISORDERS | H. LUNDBECK A/S (DK) | 2012-05-03 | — | — | US | disclosed |
| US-20120077836-A1 | METHODS OF ADMINISTERING (4AR,10AR)-1-N-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO [G] QUINOLINE-6,7-DIOL AND RELATED COMPOUNDS ACROSS THE ORAL MUCOSA, THE NASAL MUCOSA OR THE SKIN AND PHARMACEUTICAL COMPOSITIONS THEREOF | H. LUNDBECK A/S (DK) | 2012-03-29 | — | — | US | disclosed |
| US-8129530-B2 | Catecholamine derivatives and prodrugs thereof | H. LUNDBECK A/S (DK) | 2012-03-06 | — | — | US | disclosed |
| US-8129530-B2 | Catecholamine derivatives and prodrugs thereof | H. LUNDBECK A/S (DK) | 2012-03-06 | — | — | US | disclosed |
| WO-2010097092-A1 | TREATMENT OF DYSKINESIA RELATED DISORDERS | H. LUNDBECK A/S (DK) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010097091-A1 | METHODS OF ADMINISTERING (4AR, 1OAR)-I-N-PROPYL-I, 2,3,4A7 S1IO7 IOA-OCTAHYDROBENZO [G] QUINOLINE-6,7-DIOL AND RELATED COMPOUNDS ACROSS THE ORAL MUCOSA, THE NASAL MUCOSA OR THE SKIN AND PHARMACEUTICAL COMPOSITIONS THEREOF | H. LUNDBECK A/S (DK) | 2010-09-02 | — | — | WO | disclosed |
| US-20090124651-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | H. LUNDBECK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090124651-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | H. LUNDBECK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090062324-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | H. LUNDBECK A/S (DK) | 2009-03-05 | — | — | US | disclosed |
| WO-2009026934-A1 | CATECHOLAMINE DERIVATIVES USEFUL FOR THE TREATMENT OF PARKINSON' S DISEASE | H. LUNDBECK A/S (DK) | 2009-03-05 | — | — | WO | disclosed |
| US-20090062324-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | H. LUNDBECK A/S (DK) | 2009-03-05 | — | — | US | disclosed |
| WO-2009026935-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | H. LUNDBECK A/S (DK) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077836-A1 | METHODS OF ADMINISTERING (4AR,10AR)-1-N-PROPYL-1,2,3,4,4A,5,10,10A-OCTAHYDROBENZO [G] QUINOLINE-6,7-DIOL AND RELATED COMPOUNDS ACROSS THE ORAL MUCOSA, THE NASAL MUCOSA OR THE SKIN AND PHARMACEUTICAL COMPOSITIONS THEREOF | PARK7, SNCA, OPRD1 | HTR1A 12/4885ADRA1A 341/4885HSD11B1 383/4885 |
| US-20090124651-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | COMT, ADRB3, ADRB1 | HTR1A 210/4885ADRA1A 8/4885HSD11B1 129/4885 |
| US-20090062324-A1 | CATECHOLAMINE DERIVATIVES AND PRODRUGS THEREOF | COMT, ADRB3, ADRB1 | HTR1A 210/4885ADRA1A 8/4885HSD11B1 129/4885 |
| US-20120108624-A1 | TREATMENT OF DYSKINESIA RELATED DISORDERS | PARK7, ACHE, SNCA | HTR1A 469/4885ADRA1A 776/4885HSD11B1 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.